The state of biopharma in the COVID-19 world: a BioCentury & McKinsey webinar

The COVID-19 pandemic has compelled biopharma companies to rapidly adjust how they run their trials, negotiate deals and raise money. In Part 1 of a two-part webinar organized by BioCentury in collaboration with McKinsey & Co. and moderated by BioCentury Editor in Chief Simone Fishburn, three McKinsey partners assess recent clinical and financial trends and what the biopharma industry will need to consider as it grapples with the challenges of developing drugs amid a pandemic.

According to McKinsey Global Institute Senior Partner Michael Birshan, pharmaceutical companies have avoided the severe decreases in average annual shareholder returns wrought by the pandemic that have pummeled industries such as travel and energy. ...